The composite C-reactive protein-triglyceride glucose (CRP-TyG) index integrates inflammatory and metabolic dimensions and may therefore provide a more informative marker for cancer risk stratification than either component alone, particularly in hospitalized patients with diabetes. This evidence concerns the gene CRP and cancer.